CD22 and B-cell chronic lymphocytic leukemia: The CD160FCA (CD19, CD5, CD23, CD45, CD160, and CD2), CD160-ROR1FCA (CD19, CD5, CD23, CD45, CD160, ROR1, and CD2) and ERIC methods (CD19, CD20, CD5, CD43, CD79b, CD81, CD22, and CD3) all detected a high percentage of disease-specific antigen expression on the lymphoid population of patients with CLL, and a low percentage expression on both CLL-like and non-CLL MBL cases (Supplemental Figure 2; p < 0.01).